Loading...

Compugen Ltd
NASDAQ:CGEN

Watchlist Manager
Compugen Ltd Logo
Compugen Ltd
NASDAQ:CGEN
Watchlist
Price: 0.7 USD -1.41% Market Closed
Updated: Mar 25, 2023

Intrinsic Value

The intrinsic value of one CGEN stock under the Base Case scenario is 0.41 USD. Compared to the current market price of 0.7 USD, Compugen Ltd is Overvalued by 42%.

The Intrinsic Value is calculated as the average of the two valuation methods:

CGEN Intrinsic Value
Base Case
0.41 USD
Overvaluation 42%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

CGEN Profitability Score
Profitability Due Diligence

Compugen Ltd's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Negative 3-Year Average ROE
Negative 3-Year Average ROIC
Negative Free Cash Flow
Negative Operating Income
22/100
Profitability
Score

Compugen Ltd's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

CGEN Solvency Score
Solvency Due Diligence

Compugen Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Low Interest Coverage
Low Altman Z-Score
Short-Term Liabilities
Long-Term Liabilities
49/100
Solvency
Score

Compugen Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.

Financials

Balance Sheet Decomposition
Compugen Ltd

Current Assets 86.1M
Cash & Short-Term Investments 83.3M
Receivables 2.4M
Other Current Assets 362k
Non-Current Assets 8.1M
Long-Term Investments 2.8M
PP&E 3.4M
Other Non-Current Assets 1.9M
Current Liabilities 11.9M
Accounts Payable 11M
Accrued Liabilities 613k
Other Current Liabilities 325k
Non-Current Liabilities 4.6M
Other Non-Current Liabilities 4.6M
Efficiency
87%
Gross Margin
-472%
Operating Margin
-449%
Net Margin
-467%
FCF Margin
-3 130%
ROIC
-36%
ROCE
Other

CGEN Capital Structure
Compugen Ltd

Market Capitalization 60.6M USD
Total Debt 0 USD
Minority Interest 0 USD
Preferred Equity 0 USD
Cash and Equivalents 11.1M USD
Short-Term Investments 72.3M USD
Enterprise Value -22.7M USD

Wall St
Price Targets

CGEN Price Targets Summary
Compugen Ltd

There are no price targets for CGEN.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

CGEN Competitors
Compugen Ltd

CGEN Suppliers & Customers
Compugen Ltd

There is no information about
Compugen Ltd
key suppliers
Customers Map

Shareholder Return

CGEN Return Decomposition
Main factors of price return

Price Return Decomposition
is not available

It is impossible to break down the market cap return as the net margin from 5 years ago is negative.

What is price return decomposition?

CGEN Price
Compugen Ltd

1M 1M
-8%
6M 6M
-7%
1Y 1Y
-79%
3Y 3Y
-91%
5Y 5Y
-83%
Annual Price Range
0.7
52w Low
0.58
52w High
3.47
Price Metrics
Average Annual Return 41.01%
Standard Deviation of Annual Returns 110.35%
Max Drawdown -97%
Shares Statistics
Market Capitalization 60.6M USD
Shares Outstanding 86 624 643
Percentage of Shares Shorted 3.59%

Company Profile

Compugen Ltd Logo
Compugen Ltd

Country

Israel

Industry

Life Sciences Tools & Services

Market Cap

60.6M USD

Dividend Yield

0%

Description

Compugen Ltd. engages in the research, development, and commercialization of therapeutic and diagnostic biomarker product candidates including proteins and monoclonal antibodies. The firm focuses on infrastructure to discover drug targets and develop therapeutics. The firm is engaged in the research, development and commercialization of therapeutic and product candidates. The firm's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.

Contact

Holon
Azrieli Center, 26 Harokmim St. Bldg D
+97237658585.0
http://www.cgen.com/

IPO

2000-08-01

Employees

73

Officers

CEO, Pres & Director
Dr. Anat Cohen-Dayag Ph.D.
Sr. VP of Corp. & Bus. Devel.
Dr. Oliver Froescheis Ph.D.
Sr. VP of Technology Innovation
Dr. Zurit Levine
Sr. VP & Chief Medical Officer
Dr. Henry Adewoye M.D.
Chief Financial Officer
Mr. Alberto Sessa
Head of Investor Relations & Corp. Communications
Ms. Yvonne Naughton
Show More
Gen. Counsel & Corp. Sec.
Mr. Eran Ben Dor
VP of HR
Ms. Dorit Amitay
Sr. VP & Sr. Advisor of Computational Discovery
Dr. Yaron Turpaz M.B.A., Ph.D., MBA
VP Research and Discovery
Rivka Schwartz
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one CGEN stock?

The intrinsic value of one CGEN stock under the Base Case scenario is 0.41 USD.

Is CGEN stock undervalued or overvalued?

Compared to the current market price of 0.7 USD, Compugen Ltd is Overvalued by 42%.